GUANGDONG TAIANTANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.69 CNY | -5.48% |
|
-26.60% | -70.89% |
| Sales 2021 | 2.26B 313M | Sales 2022 | 725M 100M | Capitalization | 3.35B 463M |
|---|---|---|---|---|---|
| Net income 2021 | -803M -111M | Net income 2022 | -823M -114M | EV / Sales 2021 | 3.17 x |
| Net Debt 2021 | 1.45B 201M | Net Debt 2022 | 1.33B 183M | EV / Sales 2022 | 6.45 x |
| P/E ratio 2021 |
-7.1
x | P/E ratio 2022 |
-4.08
x | Employees | 955 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 75.11% |
More Fundamentals
* Assessed data
More news
| 1 day | -5.48% | ||
| 1 week | -26.60% | ||
| Current month | -44.35% | ||
| 1 month | -60.80% | ||
| 3 months | -74.54% | ||
| 6 months | -75.53% | ||
| Current year | -70.89% |
1 week
0.69
0.85
1 month
0.691.67
Current year
0.692.77
1 year
0.693.35
3 years
0.698.09
5 years
0.698.09
10 years
0.6923.93
| Managers | Title | Age | Since |
|---|---|---|---|
Shao Bin Ke
CEO | Chief Executive Officer | 45 | 07-05-15 |
Xiang Yu
DFI | Director of Finance/CFO | 54 | 12-12-25 |
Qiu Hua Xu
BRD | Director/Board Member | 61 | 13-05-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shao Fang Ke
BRD | Director/Board Member | 50 | 08-01-04 |
Shao Bin Ke
CEO | Chief Executive Officer | 45 | 07-05-15 |
Wei Quan Zhang
BRD | Director/Board Member | 44 | 09-02-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.69 | -5.48% | 1,527,800 |
| 24-04-18 | 0.73 | -5.19% | 1,635,400 |
| 24-04-17 | 0.77 | -4.94% | 2,087,800 |
| 24-04-16 | 0.81 | -4.71% | 322,200 |
| 24-04-15 | 0.85 | -4.49% | 445,800 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
Guangdong Taiantang Pharmaceutical Co Ltd is a company mainly engaged in the manufacturing of Chinese patent medicines and the primary processing of Chinese medicinal materials. The Company operates five segments. Chinese Patent Medicines Manufacturing Business segment is mainly responsible for the production and wholesale of Pibao cream, Qilin pill, Xinbao pill, Xinxin pill, Tongqiao Yixin pill, etc. Primary Processing Business segment of the traditional Chinese medicine materials is mainly responsible for planting, primary processing and sales of the ginseng and traditional Chinese medicine materials. Drug Wholesale and Retail Business segment is mainly responsible for the wholesale and retail of drugs and medical devices. Health Industry Development and Products Sales segment is mainly responsible for the development and sales of health concept real estate products. Medical Services segment is mainly responsible for the in-depth development of medical and elderly care services.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -70.89% | 77.33M | |
| +40.86% | 6.16B | |
| -16.30% | 4.49B | |
| -9.93% | 3.17B | |
| -1.58% | 3.01B | |
| -1.70% | 2.57B | |
| +37.23% | 1.8B | |
| -12.78% | 1.62B | |
| +1.02% | 1.56B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- 002433 Stock
